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Besides the direct effects, BSI has long been suspected of being a risk factor for the subsequent development of acute GVHD (aGVHD). This association was recently proven for the first time in a study by Poutsiaka et al. 2 The authors found that BSI occurring between the initiation of the conditioning regimen and 10 days after stem cell infusion was significantly associated with an increased risk of aGVHD II-IV before day 100, with cause-specific hazard ratios (HR) of 2.17. There were, however, some important limitations connected to the study; only 211 patients were included, the number of BSI before day 10 was low (n ¼ 28), and the association was at the borderline of statistical significance (P ¼ 0.04, 95% confidence interval, CI ¼ 1.05-4.49).
We retrospectively investigated risk factors for aGVHD grades II-IV before day 100, including pre-engraftment BSI, in 521 transplantations performed at our center between 2001 and 2008. The study was approved under the ethical permit DNR 425/97, issued by the ethics committee, Karolinska Institutet. In short, 514 consecutive patients undergoing 543 allogeneic HSCT were screened. The inclusion criterion of neutropenia was met in 521 transplantations performed in 493 patients (Table 1 ). All data except BSI had been collected in a prospective manner and entered in a database for research purposes. Bacterial prophylaxis with 500 mg ciprofloxacin twice daily was started 1 day before the transplantation and continued until engraftment. In the event of fever, defined as a temperature X38.5 1C once or X38.0 1C twice within 24 h, the blood cultures were drawn and empirical antibiotic therapy was instituted. The pre-engraftment phase was defined as the time from the transfusion of hematopoietic stem cells until resolution of neutropenia (ANCo0.5 Â 10 9 /L). BSI was defined as isolation of a bacterial or fungal pathogen from at least one set of blood cultures (one aerobic and one anaerobic bottle) drawn from a neutropenic patient after the start of the conditioning regimen. For coagulase-negative staphylococci and corynebacteria, isolation from at least two set of blood cultures with the same antibiogram were required. aGVHD was graded according to standard criteria. 3 Predictive analyses for aGVHD II-IV were based on the proportional hazard model for subdistribution of competing risk. A stepwise backward procedure was used to construct a set of independent predictors for each end point. All predictors with a P-value below 0.10 in the univariate analysis were considered and sequentially removed if the P-value in the multiple models was above 0.05. All tests were two-sided. Analyses were performed using the S-Plus and Statistica software (StatSoft, Tulsa, OK, USA). The Mann-Whitney U-test was used to compare continuous variables and the w 2 -test was used to compare the distribution of categorical variables.
The incidence of at least one BSI was 22% (109/497) after omitting 24 episodes of BSI, with the only microbial finding being coagulase-negative staphylococci or corynebacteria of unclear significance. All BSI occurred before the onset of aGVHD. The cumulative incidence of aGVHD II-IV before day 100 was 33%, median time to onset 24 days (range 10-98). Significant risk factors for aGVHD grades II-IV before day 100 in a multivariate analysis were myeloablative conditioning, use of melphalan or etoposide as a part of the conditioning regimen, not receiving antithymocyte globulin (ATG) as GVHD prophylaxis and preengraftment BSI (Table 2 ). Pre-engraftment BSI was also a significant risk factor for non-relapse mortality (HR 1.55, 95% CI 1.03-2.34, P ¼ 0.04) but not for aGVHD III-IV (P ¼ 0.41) in additional multivariate analyses.
The increased risk of aGVDH after myeloblative conditioning and administration of melphalan or etoposide as part of the conditioning is thought to be due to tissue damage with the release of inflammatory cytokines that leads to the activation of host APCs. 4 The finding that exclusion of ATG in the preparatory regimen significantly increased the risk of aGVHD was expected as it decreases GVHD by depleting donor T-cells in vivo. The use of ATG is most probably the main reason that the incidence of aGVHD II-IV at our center is the same in unrelated donor and matched-related donor HSCT. 5 The vast majority of the patients in the study received prophylaxis with cyclosporin and MTX (76%). The incidence of aGVHD II-IV did not differ between cyclosporin and MTX and all other prophylaxis combined (34 vs 38%). The incidence of aGVHD II-IV was also similar in all types of prophylaxis combinations, 30-38%. For this reason, we do not think that the heterogeneity of GVHD prophylaxis affects the results in any important way.
BSI before engraftment was a significant risk factor for the development of aGVHD II-IV, similar to the study by Poutsiaka et al. 2 The association between BSI and aGVHD is believed to be due to bacterial components reaching the systemic circulation and contributing to the activation of donor T cells via APCs. 6 However, the same mechanism is thought to have an important role for the significant increase in aGVHD in patients with higher degrees of gastrointestinal injury and mucosal permeability during HSCT. 7 It thus seems logical that it is the total amount of bacterial components that enters the systemic circulation that correlate with the risk of aGVHD, and that the amount needed to trigger aGVHD differs among patients, depending on whether other risk factors are present or not. If so, it may be that BSI or mucositis alone will suffice to trigger aGVHD in some patients, whereas in others the combination is required. Hence, not including mucositis due to lack of data, may hamper the statistical evaluation of the present study. In summary, in a cohort of 493 patients undergoing 521 transplantations, pre-engraftment BSI was a significant risk factor for aGVHD before day 100 in a multivariate analysis. This finding has, to our knowledge, only been reported once before in a much smaller cohort. 
